24-GU-84-MSD (003-00):A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Next-Generation Hormonal Ag

Grants and Contracts Details

StatusActive
Effective start/end date4/29/244/29/26

Funding

  • Merck Sharp & Dohme Corporation: $2.00